{"id":175322,"date":"2023-04-07T00:00:00","date_gmt":"2023-04-06T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/rimegepant-een-nieuwe-behandelingsoptie-voor-migraine\/"},"modified":"2026-04-02T19:09:15","modified_gmt":"2026-04-02T17:09:15","slug":"rimegepant-een-nieuwe-behandelingsoptie-voor-migraine","status":"publish","type":"post","link":"https:\/\/bcfi.be\/nl\/rimegepant-een-nieuwe-behandelingsoptie-voor-migraine\/","title":{"rendered":"Rimegepant: een nieuwe behandelingsoptie voor migraine"},"content":{"rendered":"<div class='summary'>Rimegepant behoort tot de klasse van de <em>calcitonin gene-related peptide<\/em> (CGRP) receptorantagonisten&#x002C; een nieuwe klasse van geneesmiddelen voor migraine&#x002C; &ldquo;gepants&rdquo; genaamd.<br \/> &nbsp;<br \/> Zowel bij toediening tijdens een migraineaanval als bij profylactische toediening is het effect van rimegepant eerder bescheiden. Met rimegepant zijn 5 &agrave; 16% m&eacute;&eacute;r pati&euml;nten twee uur na inname pijnvrij&#x002C; vergeleken met placebo. Profylactische toediening van rimegepant (om de twee dagen) geeft in de derde maand na opstart minder dan &eacute;&eacute;n migrainedag winst ten opzichte van placebo.<br \/> &nbsp;<br \/> Rechtstreeks vergelijkend onderzoek tussen rimegepant en andere &nbsp;medicatie voor de behandeling of profylaxe van migraine is nodig.<br \/> &nbsp;<br \/> Rimegepant zou een interessant alternatief kunnen zijn voor pati&euml;nten die onvoldoende respons vertonen op triptanen of met contra-indicaties voor triptanen&#x002C; maar net over die groep ontbreken nog gegevens.<br \/> &nbsp;<br \/> Ook over het nut van een aanvalsbehandeling met rimegepant bij pati&euml;nten die al profylactisch rimegepant nemen&#x002C; of die een andere profylactische behandeling krijgen&#x002C; ontbreekt gerandomiseerd onderzoek.<\/p>\n<p> Verder onderzoek is nodig om de werkzaamheid en veiligheid van rimegepant op lange termijn te bepalen.<\/p><\/div>\n<h2>CGRP-receptorantagonisten: een nieuwe klasse van antimigrainemiddelen<\/h2>\n<ul>\n<li>\n<p>Rimegepant is het eerste Europees geregistreerd antimigrainemiddel uit een nieuwe &nbsp;klasse van antimigrainemiddelen: de laagmoleculaire (non-peptide) <i>calcitonin gene-related peptide<\/i> (CGRP)-receptorantagonisten&#x002C; ook wel de <b>gepants<\/b> genoemd. CGRP is een neuropeptide dat een rol speelt bij de pathofysiologie van migraine<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282200\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Heersche<\/Author><Year>2018<\/Year><RecNum>17410<\/RecNum><DisplayText>\n\n<style face='superscript'>1<\/style>\n\n<\/DisplayText><record><rec-number>17410<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>17410<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Heersche&#x002C;A. <\/author><author>Bijlstra-Cramer&#x002C;M. A. <\/author><\/authors><\/contributors><titles><title>Erenumab; de eerste CGRP-antagonist bij migraine<\/title><secondary-title>Pharma Selecta<\/secondary-title><\/titles><pages>65-68<\/pages><volume>34<\/volume><dates><year>2018<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=17410.pdf<\/url><\/pdf-urls><\/urls><access-date>2018-10-01<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>1<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Rimegepant wordt toegediend als oraal lyofilisaat (op of onder de tong) in een sterkte van 75 mg per lyofilisaat. De dosering bedraagt 75 mg bij de acute aanval (maximaal 1x per dag) en 75 mg om de twee dagen voor profylaxe (max. 75 mg per dag). Volgens de SKP is rimegepant zowel ge&iuml;ndiceerd voor de behandeling van <strong>migraineaanvallen<\/strong> met of zonder aura bij volwassenen&#x002C; als voor de <strong>preventieve behandeling van episodische migraine<\/strong> bij volwassenen die ten minste 4 migraineaanvallen per maand hebben. Rimegepant wordt niet terugbetaald in Belgi&euml; (situatie op 01\/02\/2023&#x002C; voor de actuele prijs zie het&nbsp;<a href='https:\/\/www.bcfi.be\/nl\/chapters\/11?frag=8903122'>Repertorium<\/a>).<\/p>\n<\/li>\n<li>\n<p>Een andere klasse van antimigrainemiddelen die inwerken op CGRP of op zijn receptor&#x002C; zijn de anti-CGRP monoklonale antilichamen (enkel voor profylactische behandeling)&#x002C; waarvan er momenteel drie op de markt zijn in Belgi&euml; [zie <a href='https:\/\/www.bcfi.be\/nl\/articles\/3662?folia=3658'>Folia augustus 2021<\/a>]. Daarnaast verwacht men nog de 5HT<sub>1F<\/sub> receptoragonisten voor aanvalsbehandeling&#x002C; ook wel de ditans genoemd<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282231\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face='superscript'>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26417<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> (Europees vergund maar nog niet op de markt in Belgi&euml;).<\/p>\n<\/li>\n<li>\n<p>In de Verenigde Staten zijn naast rimegepant nog twee <b>andere gepants<\/b> vergund (situatie op 01\/02\/2023): atogepant voor migraine profylaxe en ubrogepant voor acute migraine.<\/p>\n<\/li>\n<\/ul>\n<h2>Werkzaamheid van rimegepant bij acute migraine<\/h2>\n<div class='summary'>Volgens gerandomiseerde studies is tussen 19&nbsp;en&nbsp;31% van de pati&euml;nten twee uur na inname van rimegepant pijnvrij&#x002C; dat is 5 &agrave; 16% m&eacute;&eacute;r dan met placebo. De studies includeerden overwegend vrouwen en de gemiddelde leeftijd van de deelnemers was 40 tot 42 jaar. De pati&euml;nten hadden gemiddeld 4 tot 4&#x002C;6 migraineaanvallen per maand bij de start van de studie. Pati&euml;nten met ernstige cardiovasculaire aandoeningen of psychiatrische stoornissen werden uitgesloten.<br \/> Of rimegepant ook werkzaam blijft bij herhaaldelijk gebruik voor terugkerende migraineaanvallen dient verder onderzocht.<br \/> Ook de plaats van rimegepant binnen het arsenaal van aanvalsbehandelingen is voorlopig onduidelijk.<\/div>\n<h3>Rimegepant als aanvalsbehandeling versus placebo<\/h3>\n<ul>\n<li>\n<p>Volgens <b>gerandomiseerde studies<\/b> bij in totaal 4&nbsp;700 pati&euml;nten (tussen 2 en 8 migraineaanvallen per maand&#x002C; maximaal 15 hoofdpijndagen per maand) was&#x002C; vergeleken met placebo&#x002C; <b>5 tot 16 procent m&eacute;&eacute;r pati&euml;nten<\/b> <b>pijnvrij<\/b> twee uur na inname van rimegepant 75 mg (tussen 19&nbsp;en 31% pijnvrij). Het <b>meest hinderlijke symptoom<\/b> (fotofobie&#x002C; fonofobie&#x002C; nausea of braken) was na 2 uur bij ongeveer 1 op 3 pati&euml;nten verdwenen&#x002C; versus bij ongeveer 1 op 4 pati&euml;nten met placebo.<br \/> (zie + meer info &quot;Rimegepant als aanvalsbehandeling versus andere medicatie&quot;)<\/p>\n<\/li>\n<li>\n<p>De <b>studiedeelnemers <\/b>waren overwegend vrouwen (85 &agrave; 89%) en hun gemiddelde leeftijd bedroeg 40 tot 42 jaar. Een stabiele behandeling voor migraine profylaxe was toegestaan&#x002C; op voorwaarde dat die minstens 3 maanden voordien opgestart werd. Hoeveel pati&euml;nten effectief profylactisch behandeld werden en zo ja&#x002C; met welke medicatie&#x002C; was niet vermeld.<\/p>\n<\/li>\n<li>\n<p>Pati&euml;nten met een niet-gecontroleerde&#x002C; onstabiele of recent gediagnosticeerde <b>cardiovasculaire aandoening<\/b> werden niet opgenomen in de studies vanwege het theoretisch risico op een vasoconstrictorisch effect met CGRP-remmers. Dit exclusiecriterium overlapt met de contra-indicaties voor triptanen&#x002C; en verklaart waarom zo weinig deelnemers aan de studies met rimegepant contra-indicaties hadden voor triptanen (0&#x002C;4 tot 1&#x002C;2%)<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282290\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face='superscript'>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26646<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Ook pati&euml;nten met bestaand leverlijden en pati&euml;nten met een diagnose van majeure depressie of andere <b>psychiatrische stoornissen<\/b> waren uitgesloten.<\/p>\n<\/li>\n<li>\n<p>We vonden geen gerandomiseerd onderzoek over het effect van rimegepant als aanvalsbehandeling specifiek bij pati&euml;nten die <b>al profylactisch rimegepant of andere antimigrainemedicatie nemen<\/b>. Case reports suggereren dat rimegepant de migraine-aanvallen kan verlichten bij pati&euml;nten die profylactisch <b>monoklonale antilichamen gebruiken<\/b><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282320\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282320\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282320\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>4-6<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->&#x002C; maar dat moet verder onderzocht worden.<\/p>\n<\/li>\n<\/ul>\n<h3>Rimegepant als aanvalsbehandeling versus andere medicatie<\/h3>\n<ul>\n<li>\n<p>Onderzoek over de werkzaamheid van rimegepant <b>versus andere aanvalsbehandelingen voor migraine<\/b> is schaars:<\/p>\n<ul>\n<li>\n<p>De enige <b>rechtstreeks vergelijkende<\/b> <b>RCT <\/b>was een &lsquo;<i>dose finding<\/i>&rsquo; studie met eenmalige toediening van rimegepant (in diverse doseringen)&#x002C; <b>sumatriptan 100 mg<\/b>&#x002C; of placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282348\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>4&#x002C; 6&#x002C; 7<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. In vergelijking met placebo leek de respons iets beter met sumatriptan 100 mg (35% van de pati&euml;nten pijnvrij na 2 uur) dan met rimegepant 75 mg (31&#x002C;4% pijnvrij)&#x002C; maar er was geen statistische toets voor de vergelijking rimegepant versus sumatriptan. Rimegepant en sumatriptan waren allebei werkzamer dan placebo (15&#x002C;3% pijnvrij na 2 uur) (zie + meer info).<\/p>\n<\/li>\n<li>\n<p>Een <b>netwerkmeta-analyse<\/b> van dubbelblinde RCT&rsquo;s concludeerde dat rimegepant minder werkzaam was dan de meeste triptanen&#x002C; maar die bevinding was uitsluitend gebaseerd op indirecte vergelijkingen en volgens de auteurs van de meta-analyse was er sprake van publicatiebias<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282382\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282382\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282382\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>2&#x002C; 8<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Bovendien zijn de populaties niet volledig vergelijkbaar. (zie + meer info)<\/p>\n<\/li>\n<li>\n<div class='detailed-content'>\n<ul>\n<li>Via onze bronnen vonden we de volgende RCT&rsquo;s over rimegepant als aanvalsbehandeling:<br \/> &nbsp; &nbsp; &nbsp;&#8211;&nbsp;Een fase 2 &ldquo;dose finding&rdquo; studie die pati&euml;nten randomiseerde over eenmalige toediening van&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; rimegepant (doseringen van 10 tot 600 mg)&#x002C; sumatriptan 100 mg&#x002C; en placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282415\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Marcus<\/Author><Year>2014<\/Year><RecNum>27254<\/RecNum><DisplayText>\n\n<style face='superscript'>7<\/style>\n\n<\/DisplayText><record><rec-number>27254<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27254<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Marcus&#x002C;Ronald<\/author><author>Goadsby&#x002C;Peter J<\/author><author>Dodick&#x002C;David<\/author><author>Stock&#x002C;David<\/author><author>Manos&#x002C;George<\/author><author>Fischer&#x002C;Tanya Z<\/author><\/authors><\/contributors><auth-address>Bristol-Myers Squibb&#x002C; Wallingford&#x002C; CT&#x002C; USA.<\/auth-address><titles><title>BMS-927711 for the acute treatment of migraine: a double-blind&#x002C; randomized&#x002C; placebo controlled&#x002C; dose-ranging trial.<\/title><secondary-title>Cephalalgia<\/secondary-title><\/titles><pages>114-25<\/pages><volume>34<\/volume><number>2<\/number><dates><year>2014<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23965396<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27254.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1177\/0333102413500727<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>7<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<br \/> &nbsp; &nbsp; &nbsp;&#8211;&nbsp;Drie fase 3 studies die eenmalige toediening van rimegepant 75 mg vergeleken met<br \/> &nbsp; &nbsp; &nbsp; &nbsp;placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282441\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>3&#x002C; 9&#x002C; 10<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->.\n<p> &nbsp; &nbsp; &nbsp;Alle studies includeerden volwassenen met migraine met of zonder aura&#x002C; met 2 tot<br \/> &nbsp; &nbsp; &nbsp;8&nbsp;migraineaanvallen per maand (gemiddeld 4 &agrave; 4&#x002C;6) en minder dan 15 dagen hoofdpijn per<br \/> &nbsp; &nbsp; &nbsp;maand.<br \/> &nbsp;<br \/> Primaire eindpunten:<br \/> &nbsp; &nbsp; &nbsp;&#8211;&nbsp;Percentage pati&euml;nten pijnvrij 2 uur na inname;<br \/> &nbsp; &nbsp; &nbsp;&#8211;&nbsp;Percentage pati&euml;nten bij wie het meest hinderlijke migrainesymptoom (misselijkheid&#x002C; braken&#x002C;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; fotofobie of fonofobie) verdwenen was 2 uur na inname<\/li>\n<\/ul>\n<p> Tabel: gerandomiseerde&#x002C; placebogecontroleerde studies met rimegepant voor de aanvalsbehandeling van migraine<br \/> &nbsp; <\/p>\n<table border='1' cellpadding='1' cellspacing='1' style='width:600px;'>\n<tbody>\n<tr>\n<td>Studie<\/td>\n<td>Interventie<\/td>\n<td>Klinische eindpunten<\/td>\n<td>Resultaat<\/td>\n<\/tr>\n<tr>\n<td>&lsquo;Dose finding&rsquo; RCT bij 886 volwassenen met 2 tot 7 migraineaanvallen per maand<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Marcus<\/Author><Year>2014<\/Year><RecNum>27254<\/RecNum><DisplayText>\n\n<style face='superscript'>7<\/style>\n\n<\/DisplayText><record><rec-number>27254<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27254<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Marcus&#x002C;Ronald<\/author><author>Goadsby&#x002C;Peter J<\/author><author>Dodick&#x002C;David<\/author><author>Stock&#x002C;David<\/author><author>Manos&#x002C;George<\/author><author>Fischer&#x002C;Tanya Z<\/author><\/authors><\/contributors><auth-address>Bristol-Myers Squibb&#x002C; Wallingford&#x002C; CT&#x002C; USA.<\/auth-address><titles><title>BMS-927711 for the acute treatment of migraine: a double-blind&#x002C; randomized&#x002C; placebo controlled&#x002C; dose-ranging trial.<\/title><secondary-title>Cephalalgia<\/secondary-title><\/titles><pages>114-25<\/pages><volume>34<\/volume><number>2<\/number><dates><year>2014<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23965396<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27254.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1177\/0333102413500727<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>7<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rimegepant 10-600 mg vs.<br \/> sumatriptan 100 mg vs. placebo<\/td>\n<td>Pijnvrij na 2u<br \/> (92% voltooide de studie)<\/td>\n<td>Rimegepant<br \/> 75 mg: 31&#x002C;4%<br \/> 150 mg: 32&#x002C;9%<br \/> 300 mg: 29&#x002C;7%<br \/> (p&lt;0&#x002C;05 vs placebo)<br \/> &nbsp;<br \/> Sumatriptan 35%<br \/> (p&lt;0&#x002C;05 vs placebo)<br \/> &nbsp;<br \/> Placebo 15&#x002C;3%<\/td>\n<\/tr>\n<tr>\n<td>RCT bij 1&nbsp;186 volwassenen met 2 tot 8 migraineaanvallen per maand<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Lipton<\/Author><Year>2019<\/Year><RecNum>19361<\/RecNum><DisplayText>\n\n<style face='superscript'>9<\/style>\n\n<\/DisplayText><record><rec-number>19361<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>19361<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Lipton&#x002C;R. B. <\/author><author>Croop&#x002C;R. <\/author><author>Stock&#x002C;E. G. <\/author><author>Stock&#x002C;D. A. <\/author><author>Morris&#x002C;B. A. <\/author><author>Frost&#x002C;M. <\/author><author>Dubowchik&#x002C;G. M. <\/author><author>Conway&#x002C;C. M. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>From the Departments of Neurology and Epidemiology and Population Health&#x002C; Albert Einstein College of Medicine&#x002C; and Montefiore Medical Center - both in Bronx&#x002C; NY (R.B.L.); Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT (R.C.&#x002C; E.G.S.&#x002C; D.A.S.&#x002C; B.A.M.&#x002C; M.F.&#x002C; G.M.D.&#x002C; C.M.C.&#x002C; V.C.); NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital-South London and Maudsley Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; London (P.J.G.); and the University of California&#x002C; San Francisco&#x002C; San Francisco (P.J.G.).<\/auth-address><titles><title>Rimegepant&#x002C; an oral calcitonin gene-related peptide receptor antagonist&#x002C; for migraine<\/title><secondary-title>N Engl J Med<\/secondary-title><\/titles><pages>142-149<\/pages><volume>381<\/volume><number>2<\/number><dates><year>2019<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31291516<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=19361.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1056\/NEJMoa1811090<\/electronic-resource-num><access-date>2019-08-15<\/access-date><modified-date>H\u00b0 Zen; H\u00b0 Pijn; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>9<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rimegepant 75 mg vs placebo<br \/> (eenmalige toediening)<\/td>\n<td>Pijnvrij na 2u<br \/> (90% voltooide de studie)<\/p>\n<p> Vrij van het meest hinderlijke symptoom na 2u<\/td>\n<td>19&#x002C;6% vs 12%<br \/> Verschil 7&#x002C;6% (95% BI 3&#x002C;3 tot 11&#x002C;9)<\/p>\n<p> 37&#x002C;6% vs 25&#x002C;2%<br \/> Verschil 12&#x002C;4% (95% BI 6&#x002C;9 tot 17&#x002C;9)<\/p>\n<p> &nbsp;<\/td>\n<\/tr>\n<tr>\n<td>RCT bij 1&nbsp;466 volwassenen met 2 tot 8 migraineaanvallen per maand<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2019<\/Year><RecNum>27250<\/RecNum><DisplayText>\n\n<style face='superscript'>10<\/style>\n\n<\/DisplayText><record><rec-number>27250<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27250<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Goadsby&#x002C;P. J. <\/author><author>Conway&#x002C;C. M. <\/author><author>Forshaw&#x002C;M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Lipton&#x002C;R. B. <\/author><\/authors><\/contributors><titles><title>Efficacy&#x002C; safety&#x002C; and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised&#x002C; phase 3&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>The Lancet<\/secondary-title><\/titles><pages>737-45<\/pages><volume>31<\/volume><dates><year>2019<\/year><\/dates><urls><related-urls><url>https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(19)31606-X\/fulltext<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27250.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>10<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rimegepant 75 mg vs. placebo<\/td>\n<td>Pijnvrij na 2 uur<br \/> (92% voltooide de studie)<\/p>\n<p> Vrij van het meest hinderlijke symptoom na 2 uur<\/td>\n<td>21&#x002C;2% vs 10&#x002C;9%<br \/> Verschil 10&#x002C;4% (95% BI 6&#x002C;5 tot 14&#x002C;2)<\/p>\n<p> 35&#x002C;1% vs 26&#x002C;8%<br \/> Verschil 8&#x002C;3% (95% BI 3&#x002C;4 tot 13&#x002C;2)<\/td>\n<\/tr>\n<tr>\n<td>RCT bij 1&nbsp;162 volwassenen met 2 tot 8 migraineaanvallen per maand<span class='folia-referentie-nummer'><sup>3<\/sup><\/span><sup>&#x002C; <\/sup><span class='folia-referentie-nummer'><a href='https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235479'><sup>BHV3000-301<\/sup><\/a><\/span><br \/> (nog niet <em>peer reviewed<\/em>)<\/td>\n<td>Rimegepant 75 mg vs placebo<\/td>\n<td>Pijnvrij na 2u<br \/> (93% voltooide de studie)<\/p>\n<p> Vrij van het meest hinderlijke symptoom na 2 uur<\/td>\n<td>19&#x002C;2% vs 14&#x002C;2%<br \/> Verschil 4&#x002C;9% (95% BI 0&#x002C;5 tot 9&#x002C;3)<\/p>\n<p> 36&#x002C;6% vs 27&#x002C;7%<br \/> Verschil 8&#x002C;9% (95% BI 3&#x002C;4 tot 14&#x002C;4)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p> &nbsp; <\/p>\n<ul>\n<li>Een meta-analyse gepubliceerd in JAMA<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282572\u2019> ADDIN EN.CITE <EndNote><Cite><Author>VanderPluym<\/Author><Year>2021<\/Year><RecNum>23605<\/RecNum><DisplayText>\n\n<style face='superscript'>11<\/style>\n\n<\/DisplayText><record><rec-number>23605<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>23605<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>VanderPluym&#x002C;Juliana H. <\/author><author>Halker Singh&#x002C;Rashmi B. <\/author><author>Urtecho&#x002C;Meritxell<\/author><author>Morrow&#x002C;Allison S. <\/author><author>Nayfeh&#x002C;Tarek<\/author><author>Torres Roldan&#x002C;Victor D. <\/author><author>Farah&#x002C;Magdoleen H. <\/author><author>Hasan&#x002C;Bashar<\/author><author>Saadi&#x002C;Samer<\/author><author>Shah&#x002C;Sahrish<\/author><author>Abd-Rabu&#x002C;Rami<\/author><author>Daraz&#x002C;Lubna<\/author><author>Prokop&#x002C;Larry J. <\/author><author>Murad&#x002C;Mohammad Hassan<\/author><author>Wang&#x002C;Zhen<\/author><\/authors><\/contributors><titles><title>Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis<\/title><secondary-title>JAMA<\/secondary-title><\/titles><pages>2357-2369<\/pages><volume>325<\/volume><number>23<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/doi.org\/10.1001\/jama.2021.7939|https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2781052\/jama_vanderpluym_2021_oi_210056_1623359384.25754.pdf<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=23605.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1001\/jama.2021.7939<\/electronic-resource-num><access-date>2021\/06\/02 tot 2021\/06\/15<\/access-date><modified-date>H\u00b0 Zen<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>11<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> includeerde uitsluitend gepubliceerde studies. Ze vond een grotere kans om na 2 uur pijn vrij te zijn met rimegepant dan met placebo (RR 1&#x002C;80 (95% BI 1&#x002C;52 tot 2&#x002C;13)&#x002C; <i>risk difference<\/i> 0&#x002C;09 (95% BI 0&#x002C;06 tot 0&#x002C;11)&#x002C; <i>moderate strength of evidence<\/i>).<\/li>\n<li>Een overzichtsartikel van Cohen<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282597\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Cohen<\/Author><Year>2022<\/Year><RecNum>27249<\/RecNum><DisplayText>\n\n<style face='superscript'>6<\/style>\n\n<\/DisplayText><record><rec-number>27249<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27249<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Cohen&#x002C;Fred<\/author><author>Yuan&#x002C;Hsiangkuo<\/author><author>Silberstein&#x002C;Stephen D<\/author><\/authors><\/contributors><auth-address>Jefferson Headache Center&#x002C; Department of Neurology&#x002C; Thomas Jefferson University&#x002C; 900 Walnut Street&#x002C; Suite 200&#x002C; Philadelphia&#x002C; PA&#x002C; 19107&#x002C; USA.<\/auth-address><titles><title>Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale.<\/title><secondary-title>BioDrugs<\/secondary-title><\/titles><pages>341-358<\/pages><volume>36<\/volume><number>3<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35476215<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27249.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1007\/s40259-022-00530-0<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>6<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> over rimegepant&#x002C; geciteerd in Geneesmiddelenbulletin<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282617\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face='superscript'>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26417<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->&#x002C; verwijst nog naar een andere meta-analyse<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130282634\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Gao<\/Author><Year>2020<\/Year><RecNum>27460<\/RecNum><DisplayText>\n\n<style face='superscript'>12<\/style>\n\n<\/DisplayText><record><rec-number>27460<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27460<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Gao&#x002C;Bixi<\/author><author>Yang&#x002C;Yanbo<\/author><author>Wang&#x002C;Zilan<\/author><author>Sun&#x002C;Yue<\/author><author>Chen&#x002C;Zhouqing<\/author><author>Zhu&#x002C;Yun<\/author><author>Wang&#x002C;Zhong<\/author><\/authors><\/contributors><auth-address>Department of Neurosurgery & Brain and Nerve Research Laboratory&#x002C; The First Affiliated Hospital of Soochow University&#x002C; Suzhou&#x002C; China.<\/auth-address><titles><title>Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials.<\/title><secondary-title>Front Pharmacol<\/secondary-title><\/titles><pages>1577<\/pages><volume>10<\/volume><dates><year>2020<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32038251<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27460.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.3389\/fphar.2019.01577<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>12<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Daarin zijn ook gegevens van een niet-gepubliceerde studie opgenomen. De resultaten van de meta-analyse zijn vergelijkbaar met de resultaten van de meta-analyse gepubliceerd in JAMA.<\/li>\n<li>Volgens een <a href='https:\/\/www.minerva-ebp.be\/Home\/Glossary?alpha=b#glossaryId9'>netwerkmeta-analyse<\/a> van uitsluitend indirecte vergelijkingen<span class='folia-referentie-nummer'><sup>8<\/sup><\/span> geven de meeste triptanen een grotere kans om na 2 uur pijnvrij te zijn&#x002C; vergeleken met rimegepant (odds ratio&rsquo;s van 1&#x002C;58 (95% BI 1&#x002C;07 tot 2&#x002C;33) tot 3&#x002C;13 (95% BI 2&#x002C;16 tot 4&#x002C;52)) De onderzochte populaties zijn echter niet volledig vergelijkbaar. Uit een Cochrane review<span class='folia-referentie-nummer'><sup>13<\/sup><\/span> weten we bijvoorbeeld dat de meeste studies met oraal sumatriptan pati&euml;nten includeerden met gemiddeld 1 tot 6 aanvallen per maand. In de studies met rimegepant hadden de ge&iuml;ncludeerde pati&euml;nten gemiddeld 2 tot 8 migraineaanvallen per maand.<\/li>\n<\/ul><\/div>\n<\/li>\n<\/ul>\n<\/li>\n<li>\n<p>Publicaties van studies over de werkzaamheid en veiligheid van rimegepant <b>bij pati&euml;nten voor wie andere aanvalsbehandelingen niet werken of gecontra-indiceerd zijn<\/b>&#x002C; ontbreken. Rimegepant zou een alternatief kunnen bieden voor pati&euml;nten met falen van triptanen. Onlangs werd wel een studie opgestart over de werkzaamheid en veiligheid van rimegepant bij migrainepati&euml;nten voor wie triptanen geen optie zijn [<a href='https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05509400'>Clinicaltrials.gov<\/a>].<\/p>\n<\/li>\n<li>\n<p>Van de triptanen en analgetica is geweten dat ze na verloop van tijd medicatiegerelateerde hoofdpijn kunnen geven<!--[if supportFields]><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>McCarthy<\/Author><Year>2019<\/Year><RecNum>20162<\/RecNum><DisplayText>\n\n<style face='superscript'>14<\/style>\n\n<\/DisplayText><record><rec-number>20162<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>20162<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>McCarthy&#x002C;Lucas<\/author><\/authors><\/contributors><titles><title>Orally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine<\/title><secondary-title>Annals of Internal Medicine<\/secondary-title><\/titles><pages>JC58-JC58<\/pages><volume>171<\/volume><number>10<\/number><dates><year>2019<\/year><\/dates><urls><related-urls><url>https:\/\/doi.org\/10.7326\/ACPJ201911190-058|https:\/\/watermark.silverchair.com\/acpj201911190-058.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAgowggIGBgkqhkiG9w0BBwagggH3MIIB8wIBADCCAewGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMhMktRiF2P1yY28AuAgEQgIIBvRbbKdcKZeOhyshqTylZiml6EeW2-II6AbKbgqM91YyOlFpdCBreWcz00D6nt5ruHnWORiZMNeDdRwc9HSJhXw-5Y9PYRVL3dyoATwC62SMLiWfR03qUvxwLv5Mrf4Wc1hZspquiLkMW10dSPcs6e5UXl0jLoWH_yYqWgHK4NDWpUxFk0_KaGdjO0xPbao_k-HVj-ElBs6JzIfbjTEsfwwxQGg1lU5Csprj6JAGw1ZKh8IpfOW1hspmk3thQChUHed0shBH-EN-0h35U-gp0pC9yRV70nB6QBctq_YhAZEG3DK3ck2p1eWIUOWvfiuNRnV22UU-ZlDiGVcx5A0Zzv-4n6BFGL1f4NR-5TMBuh6ARALpYVhwlQF0xpRFmwUudUVpC8efrpLFkh94jUakuy7lERjaPYjDpAnZb1d4ug_6_DpUoFFP0hp4OnzpAyJP3YMZN7YUUqzAHpl8VbEukXxvDenZgJs_AU_QDxrpBcZ0A-5PsgxU2prFV8VVKxRFXItiVgnIcHC3TPThw0hM50qmTQhVyC6JsmMjbYJhjBBkVBN0s86CPAlYoZuC-onsWRiwPVFj2N21P2Gd-7HA<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=20162.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.7326\/ACPJ201911190-058<\/electronic-resource-num><access-date>2019\/11\/16 tot 2019\/12\/01<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>14<\/sup><\/span><!--[if supportFields]><span lang=FR-BE style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:FR-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Over rimegepant zijn er voorlopig onvoldoende gegevens om zo&rsquo;n risico uit te sluiten.<\/p>\n<\/li>\n<\/ul>\n<h3>Langetermijneffecten van rimegepant als aanvalsbehandeling<\/h3>\n<ul>\n<li>\n<p>Alle gerandomiseerde studies over het effect van rimegepant als aanvalsbehandeling onderzochten eenmalige toediening. De vraag is of het effect ook behouden blijft wanneer rimegepant herhaaldelijk gebruikt wordt bij terugkerende migraineaanvallen<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283489\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face='superscript'>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26417<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Volgens een <b>post-hoc analyse<\/b> van gegevens uit een <b>open-label veiligheidsstudie<\/b> is rimegepant na &eacute;&eacute;n jaar nog steeds werkzaam bij gebruik &lsquo;indien nodig&rsquo;<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283510\u2019> ADDIN EN.CITE <\/span><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283510\u2019><span style=\u2019mso-spacerun:yes\u2019>\u00a0<\/span>ADDIN EN.CITE.DATA <![if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]><\/span><span style=\u2019mso-element:field-end\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283510\u2019><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>6&#x002C; 15<\/sup><\/span><!--[if gte mso 9]><xml> <w:data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w:data> <\/xml><![endif]--><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Er was echter veel studieuitval (ca. 4 op 10 pati&euml;nten&#x002C; reden niet vermeld)&#x002C; wat interpretatie van de bevindingen bemoeilijkt. Bijkomend onderzoek is nodig.<\/p>\n<\/li>\n<\/ul>\n<h2>Werkzaamheid van rimegepant bij migraine profylaxe<\/h2>\n<div class='summary'>Pati&euml;nten met gemiddeld 10 migrainedagen per maand&#x002C; hebben in de derde maand na opstart van profylactische inname van rimegepant om de twee dagen&#x002C; gemiddeld 0&#x002C;8 migrainedagen minder&#x002C;&nbsp;vergeleken met placebo.<br \/> Bijna de helft van de pati&euml;nten rapporteert minstens een halvering van het aantal dagen met matige tot ernstige migraine per maand voor rimegepant&#x002C; vergeleken met 41% voor placebo. Het is momenteel niet geweten of de winst behouden blijft bij een behandeling langer dan 3 maanden.<br \/> \u200bRechtstreeks vergelijkend onderzoek met andere profylactische antimigrainemiddelen moet meer duidelijkheid verschaffen over de plaats van rimegepant in het therapeutisch arsenaal. Ook het nut van preventief gebruik bij pati&euml;nten met falen van andere behandelingen voor migraine profylaxe moet onderzocht worden.<\/div>\n<h3>Profylactische behandeling met rimegepant versus placebo<\/h3>\n<ul>\n<li>\n<p>In een gerandomiseerde studie<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283545\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face='superscript'>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>22563<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--> gaf <b>profylactische inname <\/b>van rimegepant 75 mg (om de twee dagen) bij pati&euml;nten met <b>migraine<\/b> (83% vrouwen&#x002C; gemiddelde leeftijd 41 jaar&#x002C; gemiddeld 10 migrainedagen per maand bij aanvang) in de derde maand na opstart gemiddeld 0&#x002C;8 minder migrainedagen&#x002C; vergeleken met placebo. Met rimegepant was het aantal migrainedagen gedaald met gemiddeld 4&#x002C;3&#x002C;&nbsp;versus een daling van gemiddeld 3&#x002C;5 migrainedagen met placebo. Bij 49% van de pati&euml;nten verminderde het aantal dagen met matige tot ernstige migraine per maand met minstens de helft&#x002C; versus bij 41% van de pati&euml;nten met placebo.<\/p>\n<\/li>\n<li>\n<p>Er waren te weinig pati&euml;nten met chronische migraine opgenomen in de studie om uitspraak te doen over het effect van rimegepant in die subgroep.&nbsp; Daarom is de indicatie in de SKP beperkt tot <b>episodische migraine.<\/b><\/p>\n<\/li>\n<li>\n<p>Er zijn geen gegevens over de werkzaamheid van <strong>acute behandeling met rimegepant<\/strong> bij pati&euml;nten die het product al profylactisch nemen. In de studie over profylaxe was aanvalsbehandeling met rimegepant niet toegelaten.<\/p>\n<\/li>\n<li>\n<p><er de='' geen='' gegevens='' over='' van='' werkzaamheid='' zijn=''>Recent is een RCT opgestart bij <strong>pati&euml;nten met <a href='https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05518123'>falen van andere perorale middelen<\/a> voor migraineprofylaxe<\/strong>.<\/er><\/p>\n<\/li>\n<\/ul>\n<div class='detailed-content'>De profylactische studie includeerde volwassenen met migraine met aura (40%) of zonder (60%) aura. 23% van de deelnemers had een voorgeschiedenis van chronische migraine.<br \/> De pati&euml;nten moesten minstens 4 en maximaal 18 matig tot ernstige migraineaanvallen per maand hebben en minstens 6 migrainedagen doorgemaakt hebben in de maand voor randomisatie.<\/p>\n<p> Tabel: gerandomiseerde studies met rimegepant bij migraine profylaxe<br \/> &nbsp; <\/p>\n<table border='1' cellpadding='1' cellspacing='1' style='width:600px;'>\n<tbody>\n<tr>\n<td>Studie<\/td>\n<td>Interventies<\/td>\n<td>Klinische eindpunten<\/td>\n<td>Resultaten<\/td>\n<\/tr>\n<tr>\n<td>RCT bij 747 volwassenen met gemiddeld 10 migrainedagen per maand<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face='superscript'>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>22563<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]--><\/td>\n<td>Rimegepant 75 mg om de twee dagen vs. placebo<\/p>\n<p> Behandelingsduur 3 maanden (84% voltooide de behandeling&#x002C; 93% werd opgenomen in de analyse voor het primair eindpunt)<\/td>\n<td>Verandering in het aantal migrainedagen per maand (primair eindpunt)<\/p>\n<p> % pati&euml;nten met minstens 50% reductie van het aantal dagen met matige tot ernstige migraine (secundair eindpunt)<\/td>\n<td>-4&#x002C;3 vs -3&#x002C;5 dagen<br \/> Verschil -0&#x002C;8 dagen (95% BI &#8211;&nbsp;1&#x002C;46 tot &#8211;&nbsp;0&#x002C;20)<\/p>\n<p> 49% vs 41%<br \/> Verschil 8%<br \/> (95% BI 0 tot 15&#x002C; p= 0&#x002C;044)<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<h3>Rimegepant versus andere medicatie voor migraineprofylaxe<\/h3>\n<ul>\n<li>\n<p>Het effect van rimegepant lijkt van dezelfde grootteorde als dat van <b>andere behandelingen voor migraineprofylaxe<\/b>&#x002C; maar de populaties zijn niet noodzakelijk vergelijkbaar (bv. voor het aantal migraineaanvallen per maand). Rechtstreeks vergelijkend gerandomiseerd onderzoek is nodig om de plaats van rimegepant binnen het therapeutische arsenaal voor migraine profylaxe te bepalen. Een mogelijk voordeel ten opzichte van de monoklonale antilichamen is de orale toedieningsvorm&#x002C; maar ook daarover ontbreekt vergelijkend gerandomiseerd onderzoek. Een vergelijkende studie met galcenezumab is lopende (<a href='https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05127486'>CHALLENGE-MIG<\/a>)<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283586\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Cohen<\/Author><Year>2022<\/Year><RecNum>27249<\/RecNum><DisplayText>\n\n<style face='superscript'>6<\/style>\n\n<\/DisplayText><record><rec-number>27249<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27249<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Cohen&#x002C;Fred<\/author><author>Yuan&#x002C;Hsiangkuo<\/author><author>Silberstein&#x002C;Stephen D<\/author><\/authors><\/contributors><auth-address>Jefferson Headache Center&#x002C; Department of Neurology&#x002C; Thomas Jefferson University&#x002C; 900 Walnut Street&#x002C; Suite 200&#x002C; Philadelphia&#x002C; PA&#x002C; 19107&#x002C; USA.<\/auth-address><titles><title>Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale.<\/title><secondary-title>BioDrugs<\/secondary-title><\/titles><pages>341-358<\/pages><volume>36<\/volume><number>3<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35476215<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27249.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1007\/s40259-022-00530-0<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>6<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<\/ul>\n<h3>Langetermijneffecten van profylactische behandeling met rimegepant<\/h3>\n<ul>\n<li>\n<p>Drie maanden is heel kort om definitieve uitspraken te doen over het nut van rimegepant voor migraine profylaxe. We vonden geen gepubliceerd onderzoek over een langere opvolgingsperiode.<\/p>\n<\/li>\n<\/ul>\n<h2>Veiligheid van rimegepant<\/h2>\n<div class='summary'>Rimegepant lijkt goed verdragen in gerandomiseerd onderzoek. Ernstige overgevoeligheidsreacties kunnen optreden bij acuut gebruik. Post-marketing onderzoek zal meer duidelijkheid moeten verschaffen over de veiligheid bij langdurig gebruik (langer dan 3 maanden)&#x002C; in het bijzonder bij pati&euml;nten met cardiovasculaire risico&rsquo;s&#x002C; vanwege het theoretisch risico op een vasoconstrictorisch effect met CGRP-remmers. Ook de veiligheid bij gecombineerd gebruik van rimegepant met andere CGRP-remmers of met triptanen is nog onduidelijk.<\/div>\n<ul>\n<li>\n<p>In de gerandomiseerde studies over <b>aanvalsbehandeling<\/b> werd rimegepant goed verdragen: 10&#x002C;8% van de pati&euml;nten had ongewenste effecten bij eenmalige inname van rimegepant versus 8&#x002C;6% met placebo<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283616\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face='superscript'>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26646<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Misselijkheid (1&#x002C;2% vs 0&#x002C;8% met placebo) en urineweginfecties (0&#x002C;8% vs 0&#x002C;3% met placebo) werden het vaakst gerapporteerd.<\/p>\n<\/li>\n<li>\n<p>Over de veiligheid van <b>profylactische behandeling<\/b> is voorlopig nog weinig gekend. De enige gerandomiseerde studie<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283636\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face='superscript'>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>22563<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]--> duurde slechts 3 maanden en toonde geen verschil aan tussen rimegepant en placebo voor het optreden van ongewenste effecten (36% van de pati&euml;nten in beide groepen).<\/p>\n<\/li>\n<li>\n<p>Er is onvoldoende evidentie uit gerandomiseerd onderzoek om uitspraken te doen over het risico van <b>ernstige ongewenste effecten<\/b> met rimegepant als aanvalsbehandeling<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language:NL-BE; mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283670\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Halker Singh<\/Author><Year>2020<\/Year><RecNum>27247<\/RecNum><DisplayText>\n\n<style face='superscript'>17<\/style>\n\n<\/DisplayText><record><rec-number>27247<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27247<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Halker Singh&#x002C;Rashmi<\/author><author>VanderPluym&#x002C;Juliana H. <\/author><author>Morrow&#x002C;Allison S. <\/author><author>Urtecho&#x002C;Meritxell<\/author><author>Nayfeh&#x002C;Tarek<\/author><author>et al&#x002C;<\/author><\/authors><\/contributors><titles><title>Acute treatments for episodic migraine. Comparative Effectiveness Review. Number 239<\/title><secondary-title>AHRQ<\/secondary-title><\/titles><volume>December<\/volume><dates><year>2020<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27247.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>17<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. In de studie over profylactische behandeling<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><Author>Croop<\/Author><Year>2021<\/Year><RecNum>22563<\/RecNum><DisplayText>\n\n<style face='superscript'>16<\/style>\n\n<\/DisplayText><record><rec-number>22563<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>22563<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Croop&#x002C;R. <\/author><author>Lipton&#x002C;R. B. <\/author><author>Kudrow&#x002C;D. <\/author><author>Stock&#x002C;D. A. <\/author><author>Kamen&#x002C;L. <\/author><author>Conway&#x002C;C. M. <\/author><author>Stock&#x002C;E. G. <\/author><author>Coric&#x002C;V. <\/author><author>Goadsby&#x002C;P. J. <\/author><\/authors><\/contributors><auth-address>Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. Electronic address: robert.croop@biohavenpharma.com. Department of Neurology&#x002C; Albert Einstein College of Medicine&#x002C; Bronx&#x002C; NY&#x002C; USA. California Medical Clinic for Headache&#x002C; Santa Monica&#x002C; CA&#x002C; USA. Biohaven Pharmaceuticals&#x002C; New Haven&#x002C; CT&#x002C; USA. NIHR-Wellcome Trust King&apos;s Clinical Research Facility&#x002C; King&apos;s College Hospital\/SLaM Biomedical Research Centre&#x002C; King&apos;s College London&#x002C; UK; University of California&#x002C; Los Angeles&#x002C; Los Angeles&#x002C; CA&#x002C; USA.<\/auth-address><titles><title>Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial<\/title><secondary-title>Lancet<\/secondary-title><\/titles><pages>51-60<\/pages><volume>397<\/volume><number>10268<\/number><dates><year>2021<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33338437<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=22563.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1016\/S0140-6736(20)32544-7<\/electronic-resource-num><access-date>2021\/01\/02 tot 2021\/01\/15<\/access-date><modified-date>H\u00b0 Zen; TF Mig<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>16<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]--> kwamen ernstige ongewenste effecten even vaak voor met rimegepant als met placebo (1%). Grootschaliger onderzoek is nodig om dit te bevestigen.<\/p>\n<\/li>\n<li>\n<p>Wat er gebeurt na het <b>stopzetten van de behandeling <\/b>en of rebound (toename van het aantal migraine-aanvallen) optreedt bij abrupte stop is niet onderzocht. In de beschikbare studies was er geen evidentie voor een risico van rebound. Evenmin zijn er signalen van overmatig of verkeerd gebruik bij langdurige toediening van rimegepant<span class='folia-referentie-nummer'><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-theme-font:minor-latin;color:#222222;mso-ansi-language: NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-end\u2019><\/span><\/span><![endif]-->. Deze zaken moeten verder opgevolgd worden in postmarketingonderzoek.<\/p>\n<\/li>\n<li>\n<p><b>Overgevoeligheidsreacties<\/b>&#x002C; zoals dyspneu en ernstige rash&#x002C; kunnen dagen na toediening optreden. In de klinische studies kwamen ze voor bij minder dan 1% van de pati&euml;nten<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><RecNum>26645<\/RecNum><DisplayText>\n\n<style face='superscript'>18<\/style>\n\n<\/DisplayText><record><rec-number>26645<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26645<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><\/contributors><titles><title>Vydura\u00ae - Samenvatting van de Kenmerken van het Product<\/title><\/titles><dates><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26645.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>18<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>In tegenstelling tot de triptanen is rimegepant niet gecontra-indiceerd bij <b>cardiovasculaire aandoeningen<\/b><!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283753\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Schwarz<\/Author><Year>2022<\/Year><RecNum>26417<\/RecNum><DisplayText>\n\n<style face='superscript'>2<\/style>\n\n<\/DisplayText><record><rec-number>26417<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26417<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Schwarz&#x002C;E. P. <\/author><\/authors><\/contributors><titles><title>Nieuw geneesmiddel: rimegepant bij migraineaanvallen<\/title><secondary-title>Geneesmiddelenbulletin<\/secondary-title><\/titles><pages>65-8<\/pages><volume>8<\/volume><dates><year>2022<\/year><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26417.pdf<\/url><\/pdf-urls><\/urls><access-date>2022\/08\/02 tot 2022\/08\/15<\/access-date><modified-date>H\u00b0 Psy; ISDB<\/modified-date><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>2<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Pati&euml;nten met een niet-gecontroleerde&#x002C; instabiele of recent gediagnosticeerde of ernstige cardiovasculaire aandoening&nbsp;werden echter uitgesloten uit de studies&#x002C; zodat de veiligheid in die populatie nog onduidelijk is<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283766\u2019> ADDIN EN.CITE <EndNote><Cite><Author>EMA<\/Author><RecNum>26646<\/RecNum><DisplayText>\n\n<style face='superscript'>3<\/style>\n\n<\/DisplayText><record><rec-number>26646<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26646<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>EMA&#x002C;<\/author><\/authors><\/contributors><titles><title>EPAR-Assessment Report Vydura\u00ae<\/title><\/titles><dates><\/dates><urls><related-urls><url>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26646.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>3<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Over de veiligheid van gecombineerd gebruik van rimegepant met<b> triptanen<\/b> is geen uitspraak mogelijk bij gebrek aan gegevens. In de studies over aanvalsbehandeling waren triptanen niet toegelaten in de eerste 48u na inname van rimegepant. In de studie over profylactische behandeling waren triptanen wel toegelaten&#x002C; maar de auteurs vermeldden niet hoe vaak dit gebeurde (voor alle &ldquo;rescue&rdquo; medicatie samen was dit in de laatste maand van de studie gem. 3&#x002C;7 dagen met rimegepant vs. 4 dagen met placebo&#x002C; verschil niet statistisch significant).<\/p>\n<\/li>\n<li>\n<p>Over gelijktijdig gebruik van rimegepant met <b>monoklonale antilichamen<\/b> voor migraineprofylaxe zijn de beschikbare gegevens geruststellend&#x002C; maar de evidentie is te beperkt en van te korte duur om definitieve uitspraken te doen over de veiligheid ervan<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283795\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Cohen<\/Author><Year>2022<\/Year><RecNum>27249<\/RecNum><DisplayText>\n\n<style face='superscript'>6<\/style>\n\n<\/DisplayText><record><rec-number>27249<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27249<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Cohen&#x002C;Fred<\/author><author>Yuan&#x002C;Hsiangkuo<\/author><author>Silberstein&#x002C;Stephen D<\/author><\/authors><\/contributors><auth-address>Jefferson Headache Center&#x002C; Department of Neurology&#x002C; Thomas Jefferson University&#x002C; 900 Walnut Street&#x002C; Suite 200&#x002C; Philadelphia&#x002C; PA&#x002C; 19107&#x002C; USA.<\/auth-address><titles><title>Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale.<\/title><secondary-title>BioDrugs<\/secondary-title><\/titles><pages>341-358<\/pages><volume>36<\/volume><number>3<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35476215<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27249.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1007\/s40259-022-00530-0<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>6<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->. Voorzichtigheid is geboden omdat CGRP betrokken is bij verschillende fysiologische processen en het combineren van CGRP-remmers in theorie kan leiden tot hypertensie of ischemische events. Langetermijnstudies in grotere onderzoekspopulaties zijn nodig om na te gaan bij welke subgroepen combinatietherapie mogelijk baat heeft dan wel extra risico&rsquo;s inhoudt<!--[if supportFields]><span style=\u2019font-size: 12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span><span style=\u2019mso-bookmark:_Hlk130283813\u2019> ADDIN EN.CITE <EndNote><Cite><Author>Pellesi<\/Author><Year>2022<\/Year><RecNum>27354<\/RecNum><DisplayText>\n\n<style face='superscript'>19<\/style>\n\n<\/DisplayText><record><rec-number>27354<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>27354<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><authors><author>Pellesi&#x002C;Lanfranco<\/author><\/authors><\/contributors><titles><title>Combining two CGRP inhibitors to treat migraine<\/title><secondary-title>Expert Opinion on Drug Safety<\/secondary-title><\/titles><pages>1135-36<\/pages><volume>21<\/volume><number>9<\/number><dates><year>2022<\/year><\/dates><urls><related-urls><url>https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36189628<\/url><\/related-urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=27354.pdf<\/url><\/pdf-urls><\/urls><electronic-resource-num>10.1080\/14740338.2022.2130890<\/electronic-resource-num><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>19<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Er zijn onvoldoende gegevens over het gebruik van rimegepant tijdens de <b>zwangerschap<\/b>. Dit wordt uit voorzorg afgeraden.<\/p>\n<\/li>\n<li>\n<p><b>Interacties<\/b>: rimegepant is een substraat van CYP3A4 en van P-gp. De gelijktijdige toediening met krachtige CYP3A4-inhibitoren of met (matig) krachtige CYP3A4-inductoren wordt niet aangeraden. In geval van gelijktijdig gebruik van matig krachtige CYP3A4-inhibitoren of van krachtige P-gp-inhibitoren moet de inname van een tweede dosis rimegepant binnen de 48 uur vermeden worden (zie Tabel Ic en Tabel Id in <a href='https:\/\/www.bcfi.be\/nl\/chapters\/1?frag=9990243'>Inleiding 6.3.<\/a>)<!--[if supportFields]><span style=\u2019font-size:12.0pt; line-height:150%;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family: 'Times New Roman';mso-ansi-language:NL-BE;mso-fareast-language:EN-US; mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element:field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><RecNum>26645<\/RecNum><DisplayText>\n\n<style face='superscript'>18<\/style>\n\n<\/DisplayText><record><rec-number>26645<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26645<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><\/contributors><titles><title>Vydura\u00ae - Samenvatting van de Kenmerken van het Product<\/title><\/titles><dates><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26645.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>18<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p><b>Bijzondere voorzorgen<\/b>: rimegepant moet worden vermeden bij pati&euml;nten met ernstige leverinsuffici&euml;ntie<!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-begin\u2019><\/span> ADDIN EN.CITE <EndNote><Cite><RecNum>26645<\/RecNum><DisplayText>\n\n<style face='superscript'>18<\/style>\n\n<\/DisplayText><record><rec-number>26645<\/rec-number><foreign-keys><key app='EN' db-id='9estwffrmd2vsler0f4pa2de25fzxpr005sw' timestamp='0'>26645<\/key><\/foreign-keys><ref-type name='Journal Article'>17<\/ref-type><contributors><\/contributors><titles><title>Vydura\u00ae - Samenvatting van de Kenmerken van het Product<\/title><\/titles><dates><\/dates><urls><pdf-urls><url>https:\/\/lib.bcfi-cbip.be\/librarian\/pdfviewer.php?file=26645.pdf<\/url><\/pdf-urls><\/urls><\/record><\/Cite><\/EndNote><span style=\u2019mso-element:field-separator\u2019><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>18<\/sup><\/span><!--[if supportFields]><span style=\u2019font-size:12.0pt;line-height:150%;font-family:'Calibri'&#x002C;sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font: minor-latin;mso-bidi-font-family:'Times New Roman';mso-ansi-language:NL-BE; mso-fareast-language:EN-US;mso-bidi-language:AR-SA\u2019><span style=\u2019mso-element: field-end\u2019><\/span><\/span><![endif]-->.<br \/> &nbsp;<\/p>\n<\/li>\n<\/ul>\n<h2>Commentaar van het BCFI<\/h2>\n<ul>\n<li>\n<p>Onze boodschappen over rimegepant komen grotendeels overeen met die over de monoklonale antilichamen bij migraine [zie <a href='https:\/\/www.bcfi.be\/nl\/articles\/3662?folia=3658'>Folia augustus 2021<\/a>]. Een deel van de pati&euml;nten heeft allicht baat bij deze nieuwe medicatie&#x002C; maar het is niet duidelijk waarin &#39;responders&#39; verschillen van &#39;non-responders&#39;. Dat dient verder uitgeklaard in toekomstig onderzoek.<\/p>\n<\/li>\n<li>\n<p>Bij pati&euml;nten met een migraineaanval is 19&nbsp;tot 31% van de pati&euml;nten pijnvrij twee uur na inname van rimegepant; 5 tot 16% m&eacute;&eacute;r dan met placebo. Het&nbsp;effect lijkt van dezelfde grootte-orde als dat van andere antimigrainemiddelen&#x002C; maar alleen studies die dezelfde populaties onderzoeken kunnen hier meer inzicht in geven. Om de plaats van rimegepant in het beschikbare therapeutisch arsenaal beter te kunnen bepalen is rechtstreeks vergelijkend onderzoek nodig.<\/p>\n<\/li>\n<li>\n<p>Migrainelijders bij wie andere behandelingen falen of gecontra-indiceerd zijn&#x002C; hebben mogelijk baat bij een behandeling met rimegepant&#x002C; maar net over deze groep ontbreekt gerandomiseerd onderzoek. Ook over de risico&rsquo;s en baten van gecombineerd gebruik met monoklonale antilichamen is meer onderzoek nodig.<\/p>\n<\/li>\n<li>\n<p>Profylactische behandeling met rimegepant levert bij pati&euml;nten minder dan &eacute;&eacute;n migrainevrije dag extra op per maand. Hoewel elke dag zonder migraine winst betekent voor de pati&euml;nt&#x002C; is het belangrijk om geen valse verwachtingen te cre&euml;ren. Er is geen garantie dat de behandeling aanslaat en bovendien is de behandeling niet curatief.<\/p>\n<\/li>\n<li>\n<p>Opvallend is de grote placeborespons in een populatie van pati&euml;nten met ernstige migraine (de pati&euml;nten hadden bij aanvang gemiddeld 4 &agrave; 4&#x002C;6 aanvallen per maand in de studies over acute migraine en gemiddeld 10 migrainedagen per maand in de studie over profylaxe).<\/p>\n<\/li>\n<li>\n<p>Men kan zich afvragen of de hoge kostprijs van rimegepant&#x002C; die met ongeveer &euro;30 per tablet ver boven de prijs ligt van de meeste andere antimigrainemiddelen (uitgezonderd de monoklonale antilichamen)&#x002C; in verhouding staat tot de winst. De maatschappelijke kost van ernstige migraine dient daarbij in rekening genomen te worden.<\/p>\n<\/li>\n<li>\n<p>Gezien migraine een chronische aandoening is&#x002C; is de kans re&euml;el dat de profylactische behandeling jarenlang genomen wordt. De placebogecontroleerde studies met rimegepant duren hooguit 3 maanden&#x002C; zodat er nog vele&nbsp;vraagtekens blijven over de werkzaamheid en veiligheid bij langdurig gebruik. Bovendien ontbreken goed uitgevoerde studies over wat er gebeurt als de behandeling wordt stopgezet.<\/p>\n<\/li>\n<li>\n<p>De klinische studies hebben geen ernstige ongewenste effecten aan het licht gebracht&#x002C; maar ze vonden plaats in een geselecteerde populatie. Postmarketing onderzoek dient uitsluitsel te geven over de veiligheid van rimegepant&#x002C; in het bijzonder bij pati&euml;nten met ernstige cardiovasculaire aandoeningen of met psychiatrische stoornissen.<\/p>\n<\/li>\n<li>\n<p>Over de werkzaamheid en veiligheid van de CGRP-receptorantagonisten bij kinderen en adolescenten is geen uitspraak mogelijk&#x002C; omdat gerandomiseerd onderzoek ontbreekt.<\/p>\n<\/li>\n<\/ul>\n<h2>Bronnen<\/h2>\n<p><span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>1&nbsp;<\/span>Heersche A&#x002C; Bijlstra-Cramer MA. Erenumab; de eerste CGRP-antagonist bij migraine. Pharma Selecta 2018;34:65-8.<\/span><br \/> <span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>2&nbsp;&nbsp;<\/span>Schwarz EP. Nieuw geneesmiddel: rimegepant bij migraineaanvallen. Geneesmiddelenbulletin 2022;8:65-8.<br \/> <span class='folia-referentie-nummer'>3&nbsp;<\/span>EMA. EPAR-Assessment Report Vydura&reg;. <a href='https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura'>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vydura<\/a><br \/> <span class='folia-referentie-nummer'>4<\/span>&nbsp;The Medical Letter on Drugs and Therapeutics. Rimegepant (Nurtec ODT) for acute treatment of migraine. The Medical Letter on Drugs and Therapeutics 2020;62:70-2. <a href='https:\/\/secure.medicalletter.org\/TML-article-1597d'>https:\/\/secure.medicalletter.org\/TML-article-1597d<\/a><br \/> <span class='folia-referentie-nummer'>5<\/span>&nbsp;Mullin K&#x002C; Kudrow D&#x002C; Croop R&#x002C; et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020;94:e2121-e5.doi:10.1212\/WNL.0000000000008944<\/span><br \/> <span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>6<\/span>&nbsp;Cohen F&#x002C; Yuan H&#x002C; Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale. BioDrugs 2022;36:341-58.doi:10.1007\/s40259-022-00530-0<br \/> <span class='folia-referentie-nummer'>7<\/span>&nbsp;Marcus R&#x002C; Goadsby PJ&#x002C; Dodick D&#x002C; et al. BMS-927711 for the acute treatment of migraine: a double-blind&#x002C; randomized&#x002C; placebo controlled&#x002C; dose-ranging trial. Cephalalgia 2014;34:114-25.doi:10.1177\/0333102413500727<br \/> <span class='folia-referentie-nummer'>8<\/span>&nbsp;Yang C-P&#x002C; Liang C-S&#x002C; Chang C-M&#x002C; et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 2021;4:e2128544.doi:10.1001\/jamanetworkopen.2021.28544<br \/> <span class='folia-referentie-nummer'>9<\/span>&nbsp;Lipton RB&#x002C; Croop R&#x002C; Stock EG&#x002C; et al. Rimegepant&#x002C; an oral calcitonin gene-related peptide receptor antagonist&#x002C; for migraine. N Engl J Med 2019;381:142-9.doi:10.1056\/NEJMoa1811090<br \/> <span class='folia-referentie-nummer'>10<\/span>&nbsp;Croop R&#x002C; Goadsby PJ&#x002C; Conway CM&#x002C; et al. Efficacy&#x002C; safety&#x002C; and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised&#x002C; phase 3&#x002C; double-blind&#x002C; placebo-controlled trial. The Lancet 2019;31:737-45.doi:<a href='https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X'>https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X<\/a><br \/> <span class='folia-referentie-nummer'>11<\/span>VanderPluym JH&#x002C; Halker Singh RB&#x002C; Urtecho M&#x002C; et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA 2021;325:2357-69.doi:10.1001\/jama.2021.7939<br \/> <span class='folia-referentie-nummer'>12<\/span>&nbsp;Gao B&#x002C; Yang Y&#x002C; Wang Z&#x002C; et al. Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 2020;10:1577.doi:10.3389\/fphar.2019.01577<br \/> <span class='folia-referentie-nummer'>13<\/span>&nbsp;Derry CJ&#x002C; Derry S&#x002C; Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615.doi:10.1002\/14651858.CD008615.pub2<br \/> <span class='folia-referentie-nummer'>14<\/span>&nbsp;McCarthy L. Orally disintegrating rimegepant increased freedom from pain and from most bothersome symptom at 2 h in acute migraine. Annals of Internal Medicine 2019;171:JC58-JC.doi:10.7326\/ACPJ201911190-058<br \/> <span class='folia-referentie-nummer'>15<\/span>&nbsp;Johnston K&#x002C; Harris L&#x002C; Powell L&#x002C; et al. Monthly migraine days&#x002C; tablet utilization&#x002C; and quality of life associated with Rimegepant &#8211; post hoc results from an open label safety study (BHV3000-201). J Headache Pain 2022;23:10.doi:10.1186\/s10194-021-01378-5<br \/> <span class='folia-referentie-nummer'>16<\/span>&nbsp;Croop R&#x002C; Lipton RB&#x002C; Kudrow D&#x002C; et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3&#x002C; randomised&#x002C; double-blind&#x002C; placebo-controlled trial. Lancet 2021;397:51-60.doi:10.1016\/S0140-6736(20)32544-7<br \/> <span class='folia-referentie-nummer'>17<\/span>&nbsp;Halker Singh R&#x002C; VanderPluym JH&#x002C; Morrow AS&#x002C; et al. Acute treatments for episodic migraine. Comparative Effectiveness Review. Number 239. AHRQ 2020;December. <a href='https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/'>https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK566246\/<\/a><br \/> <span class='folia-referentie-nummer'>18<\/span>&nbsp;Anonymous. Vydura&reg; &#8211; Samenvatting van de Kenmerken van het Product.<br \/> <span class='folia-referentie-nummer'>19<\/span>&nbsp;Pellesi L. Combining two CGRP inhibitors to treat migraine. Expert Opinion on Drug Safety 2022;21:1135-36.doi:10.1080\/14740338.2022.2130890<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rimegepant behoort tot de klasse van de calcitonin gene-related peptide  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43,14916],"tags":[20213,20224],"class_list":["post-175322","post","type-post","status-publish","format-standard","hentry","category-nieuw","category-2023-nl","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/comments?post=175322"}],"version-history":[{"count":2,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175322\/revisions"}],"predecessor-version":[{"id":180280,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175322\/revisions\/180280"}],"wp:attachment":[{"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/media?parent=175322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/categories?post=175322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcfi.be\/nl\/wp-json\/wp\/v2\/tags?post=175322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}